Analiz zarubezhnogo rynka regenerativnoy meditsiny



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

В обзоре представлен анализ современного состояния и перспектив развития зарубежного рынка регенеративной медицины. Проведено обобщение коммерческих аспектов развития отрасли за последние 20 лет, а также представлены прогнозы по ее развитию на период до 2018 г.

About the authors

VL Zorin

A I Zorina

V R Cherkasov

References

  1. Деев Р.В. Анализ рынка клеточных препаратов для коррекции патологии скелетных тканей. Клет. транспл. и ткан, инженер. 2006; 2(4): 78-83.
  2. Волков А.В. Краткий обзор коммерчески доступных клеточных продуктов для восстановления кожных покровов. Клет. транспл. и ткан. инженер. 2006; 4(6]; 62-5.
  3. Иванов А.А. Перспективы применения стволовых клеток в медицине. В кн.: Биология стволовых клеток и клеточных технологий. Москва: «Медицина», «Шико»; 2009; 1: 31-43.
  4. Kemp P. History of regenerative medicine: looking backwards to move forwards. Reg. Med. 2006; 1(5): 653-69.
  5. Mason C, Dunnil P. Lessons for nascent regenerative medicine industry from the biotech sector. Reg. Med. 2007; 2(5]: 753-6.
  6. Lysaght M.J., Hazlehurst A.L. Tissue engineering: the end of the beginning. Tissue Eng. 2004; 10: 309-20.
  7. Eisenbud D. Founding and growth of a start-up company in the cell-based therapeutic arena. Proceedings of 4th Annual Commercialisation of Tissue Engineering and Cell Therapy, Marcus Evans Conference; 2006 Dec.14-15; London, UK.
  8. MacKay G. Analysing the path for the reimbursement of eel therapies in the USA. Proceedings of 4th Annual Commercialisation of Tissue Engineering and Cell Therapy, Marcus Evans Conference; 2006 Dec.14-15; London, UK. 9. Stem Cell Summit. Analysis and market forecast, 2009-2019. Wayne: RPY Publications; 2009.
  9. Marston W.A. Dermagraft, a bioengineered human dermal equivalent for the treatment of chronic nonhealing diabetic foot ulcer. Expert. Rev. Med. Devices 2004; 1: 21-31.
  10. Omar A.A., Mavor A.I., Jones A.M., Homer-Vanniasinkam S. Treatment of venous leg ulcers with Dermagraft. Eur. J. Vase. Endovasc. Surg. 2004; 27: 666-72.
  11. Jones I., Currie L., Martin R. A guide to biological skin substitutes. Br. J. Plast. Surg. 2002; 55: 185-93.
  12. Strietzel F.P. Tissue-engineered bone for lateral alveolar ridge augmentation: a case report. Int. J. Oral Maxillofac. Implants 2006; 21: 131-5.
  13. Schmelzeisen R., Schimming R., Sittinger M. Making bone: implant insertion into tissue-engineered bone for maxillary sinus floor augmentation -a preliminary report. J. Craniomaxillofac. Surg. 2003; 31: 34-9. 15. Erggelet C, Sittinger M., Lahm A. The arthroscopic implantation of autologous chondrocytes for the treatment of full-thickness cartilage defects of the knee joint. Arthroscopy 2003; 19: 108-10.
  14. Boss W.K. Jr, Usal H, Fodor P.В., Chernoff G. Autologous cultured fibroblasts: a protein repair system. Ann. Plast. Surg. 2000; 44(5): 536^12.
  15. Beary III J.F., Siegfried J.D, Tavares R. US Drug and Biologic Approvals in 1997. Drug Dev. Res. 1998; 44: 114-29.
  16. Marcacci M., Berruto M., Brocchetta D. et al. Articular cartilage engineering with Hyalograft C: 3-year clinical results. Clin. Orthop. Relat. Res. 2005; 435: 96-105.
  17. Vibe-Hansen R., Aesculai S. inventors; Methods, instruments and kit for autologous chondrocyte transplantation. Patent WO 98/ 08469.1998.
  18. Grifka J., Anders S., Lu.hnert J. et al. Regeneration von Gelenkknorpel durch die autologe Chondrozytentransplantation. Arthroskopy 2000; 13: 113-22.
  19. Litzke L.E., Wagner E., Baumgaertner W. et al. Repair of extensive articular cartilage defects in horses by autologous chondrocyte transplantation. Ann. Biomed. Eng. 2004; 32: 57-69.
  20. Erggelet C, Sittinger M., Lahm A. The arthroscopic implantation of autologous chondrocytes for the treatment of full-thickness cartilage defects of the knee joint. Arthroscopy 2003; 19: 108-10.
  21. Vanlauwe J. An international multicentric prospective randomized controlled trial for cartilage repair using microfracture versus autologous chondrocyte implantation with ChondroCelect®: scientific background and trial design. In: Proceedings of Annual Flemish Biotech Convention: Knowledge for Growth. 2005; Ghent, Belgium: FlandersBio.
  22. Arbel R., Morag G., Gabriel A. etal. BioCart™ II: a novel matrix-assisted implant for multiple joints and lesion types. In: Proceedings of 6th Combined Meeting of the Orthopaedic Research Societies. 2007; Bologna, Italy.
  23. Strietzel F.P. Tissue-engineered bone for lateral alveolar ridge augmentation: a case report. Int. J. Oral Maxillofac. Implants. 2006; 21: 131-5.
  24. Schmelzeisen R., Schimming R., Sittinger M. Making bone: implant insertion into tissue-engineered bone for maxillary sinus floor augmentation -a preliminary report. J. Craniomaxillofac. Surg. 2003; 31: 34-9.
  25. Bobic V. Tissue repair techniques of the future: options for articular cartilage injury. Medscape Orthop. Sports Med.: eJournal. 2000; 4(1).
  26. Melnikova I. Promise of Stem Cell Therapy: Challenges and Opportunities. 2006; Boston: MEDACorp, USA.
  27. Heimbach D.M., Warden G.D., Luterman A. et al. Multicenter postapproval clinical trial of Integra dermal regeneration template for burn treatment. J. Burn Care Rehabil. 2003; 24: 42-8.
  28. Winfrey M.E., Cochran M, Hegarty M.T. A new technology in burn therapy: INTEGRA artificial skin. Dimens. Crit Care Nurs. 1999; 18: 14-20.
  29. Wright K.A., Nadire K.B., Busto P. et al. Alternative delivery of keratinocytes using a polyurethane membrane and the implications for its use in the treatment of fullthickness burn injury. Burns. 1998; 24: 7-17.
  30. Compton C.C., Gill J.M., Bradford D.A. et al. Skin regenerated from cultured epithelial autografts on full-thickness burn wounds from 6 days to 5 years after grafting. A light, electron microscopic and immunohistochemical study. Lab Invest. 1989; 60: 600-12.
  31. Noordenbos J, Dore C, Hansbrough J.F. Safety and efficacy of TransCyteforthe treatment of partial-thickness burns. J. Burn Care Rehabil. 1999; 20: 275-81.
  32. Kumar R.J., Kimble R.M., Boots R, Pegg S.P. Treatment of partialthickness burns: a prospective, randomized trial using Transcyte. ANZ. J. Surg. 2004; 74: 622-6.
  33. Navarro F.A., Stoner M.L., Park C.S. et al. Sprayed keratinocyte suspension accelerate epidermal coverage in a pocine microwound model. J. Burn Care Rehabil. 2000; 21(6): 513-8.
  34. AlloDem® regenerative dermis, www.lifecell.com <http://www.lifecell.com>.
  35. Eaglstein W.H., Falanga V. Tissue engineering and the development of Apligraf, a human skin equivalent. Clin. Ther. 1997; 19: 894-905.
  36. Cavorsi J., Vicari F., Wirthlin D.J. et al. Best-practice algorithms for the use of a bilayered living cell therapy (Apligraf) in the treatment of lowerextremity ulcers. Wound. Repair Regen. 2006; 14: 102-9.
  37. Gentzkow G.D., Iwasaki S.D., Hershon K.S. etal. Use of dermagraft, a cultured human dermis, to treat diabetic foot ulcers. Diabetes Care. 1996; 19(4): 350-4.
  38. Marston W.A. Dermagraft, a bioengineered human derma equivalent for the treatment of chronic nonhealing diabetic foot ulcer. Expert. Rev. Med. Devices 2004; 1: 21-31.
  39. Tausche A.K., Skaria M., ВцМеп L. et al. An autologous epidermal equivalent tissue-engineered from follicular outer root sheath keratinocytes is as effective as split-thickness skin autograft in recalcitrant vascular leg ulcers. Wound. Repair Regen. 2003; 11: 248-52.
  40. Vaillant L. Treatment of venous leg ulcers with Epibase. A prospective study. Preliminary results. Ann. Dermatol. Venereol. 2002; 129(10): 1245-6.
  41. Soler С Genevrier Biotechnology Center: production of autologous epidermal sheets (Epibase). Ann. Dermatol. Venereol. 2002; 129(10): 1239-41.
  42. Still J., Glat P., Silverstein P. et al. The use of a collagen sponge/ living cell composite material to treat donor sites in burn patients. Burns 2003; 29(8): 837-41.
  43. Johnsen S., Ermuth Т., Tanczos E. et al. Treatment of therapy-refractive ulcera cruris of various origins with autologous keratinocytes in fibrin sealant. Vasa 2005; 34(1): 25-9.
  44. CaravaggiC, DeGiglioR., Pritelli С et al. HYAFF11-based autologous dermal and epidermal grafts in the treatment of noninfected diabetic plantar and dorsal foot ulcers: a prospective, multicenter, controlled, randomized clinical trial. Diabetes Care 2003; 26(10): 2853-9.
  45. Moustafa M., Simpson C, Glover M. et al. A new autologous keratinocyte dressing treatment for non-healing diabetic neuropathic foot ulcers. Diabetic Med. 2004; 21(71:786-9.
  46. BioTissue Technologies AG. BioSeed and BioSeed-M: Product description, technology and clinical evaluation. BioTissue Technologies AG , <http://www>. biotissue-tec. com.
  47. Westerhof W., Lontz W., Vanscheidt W., Braathen L. Vitiligo: news in surgical treatment. J. Eur. Acad. Dermatol. Venereol. 2001; 15(6): 510-1.
  48. Kemp P. Growing Human Fibroblasts for Regeneration and Repair. Advances in aesthetic cellular rejuvenation. 2007; 1-12. <http://> www.vavelta.com/vavelta/tools/downlib/9153_vavelta_advances-2_04.pdf <http://www.vavelta.com/vavelta/tools/downlib/9153_vavelta_advances-2_04.pdf>
  49. Румянцев А.Г., Масчан А.А. Трансплантация гемопоэтических стволовых клеток у детей. МИД.: Москва; 2003: 912.
  50. Исаев А.А., Квашнина Н.В., Приходько А.В. Банки пуповинной крови - деятельность, ее регулирование, перспективы. Клет. Транспл. 2006; КЗ): 88-91.
  51. McGuckin СР., Forraz N. Cord blood stem cells - potentials and realities. In: Polack J., editor. Advances in tissue engineering. London: Imperial college press; 2008: 123-42.
  52. Sullivan M.J. Banking on cord blood stem cells. Nature Rev. Cancer. 2008; 8(7): 594-63.
  53. Майорова O.A., Румянцев С.А., Яковлева M.B. Пуповинная кровь как трансплантационный материал. В кн.: Биология стволовых клеток и клеточных технологий. М.: «Медицина», «Шико», 2: 381-412.
  54. Polack J., Mantalaris S., Harding S. editors. Advances in tissue engineering. London: Imperial college press. 2008: 498.
  55. Lysaght M.J. Tissue engineering: great expectation. In: London Regenerative Medicine Network event. London, UK; 2006.
  56. Powers L. Examining Early Stage Funding and Developing Spin-Out Opportunities. Commercialisation of tissue engineering and cell therapy, Proceedings of the Marcus Evans Conference; London, UK; 2006.
  57. Prescott С The promise of stem cells: a venture capital perspective. In: Polack J., editor. Advances in tissue engineering. London: Imperial college press; 2008: 491-500.
  58. Gottlieb S. California's stem-cell follies, 2004, www.forbes.com <http://www.forbes.com>.
  59. Stem cells for safer medicine - a public private partnership, www.sc4sm.org <http://www.sc4sm.org>
  60. The Impact of the Convergence of Biologic with the Medical Device Industry, MTLF Report. In: Medical Technology Leadership Forum, 2007 June 4-5; Georgia Institute of Technology, Atlanta, USA.
  61. .Havrilla M. Regenerative Medicine: Big Pharma's Next Frontier, <http://seekingalpha.com> /article/ 1 0651 8-regenerative-medicine-big-pharma-s- next-frontier?source = commenter.
  62. Heiko G. Does Regenerative Medicine Enable Index Investements? Special Edition: Regenerative Medicine S. Stem Cells. Bio Word EUROPE, 2007; (Special Edition 1): 17-23.
  63. Nerem R.M. Tissue engineering: past, present, and future. In: Polack J., editor. Advances in tissue engineering. London: Imperial college press; 2008: 3-12.
  64. Bush G.W. President discusses stem cell research, August 2001, www.whitehouse.gov/news/releases/2001/08/20010809-2.html <http://www.whitehouse.gov/news/releases/2001/08/20010809-2.html>.
  65. Geron Corporation. Geron Receives FDA Clearance to Begin World's First Human Clinical Trial of Embryonic Stem Cell-Based Therapy. News Release. 2009 Jan. 23, <http://www.geron.com> /investors /factsheet/ pressview.aspx?id = 1148.
  66. Intercytex Group pic. Phase III results of Cyzact® fail to meet primary endpoint. Press Releases. 2009 Feb. 20th, <http://www.intercytex.com/icx/> news/releases/2009/2009-02-23/2009-02-23.pdf.
  67. Osiris Therapeutics Awarded Department of Defense Contract for Prochymal™ Fully Valued at $224.7 Million. 2008 Jan. 3, <http://www.osiristx.com/> pdf PR%2065%2003Jan08%200siris%20Wins%20DoD%20Contract.pdf.
  68. Osiris and Genzyme Partner to Develop Medical Countermeasures for Nuclear and Radiological Threats. 2007, July 26, <http://www.osiris.com/pdf/PR%2046> % 2025July07% 200siris%20and%20Genzyme%20form%20Partnership.pdf.
  69. Narvid M. Stem Cell Markets - an Analysts View. In: Regenerative Medicine & Stem Cells, Special Edition. Bio Word EUROPE. 2007: 20-3.
  70. Schrattenholz A., Klemm M. How human embryonic cell research can impact in-vitro drug screening technologies of the future. In: Drug Testing In Vitro: Breakthroughs and Trends in Cell Culture Technology. Marx U., Sandig V, editors. WILEY-VCH Verlag Gmbh Co; 2007: 205-28.
  71. Nerem R.M. Cell-based therapies: from basic biology to replacement, repair, and regeneration. Biomater. 2007; 28: 5074-7.
  72. Ahsan Т., Nerem R.M. Bioengineered tissues: the science, the technology, and the industry. Orthod. Craniofac. Res. 2005; 8: 134-40.
  73. The Impact of the Convergence of Biologic with the Medical Device Industry, MTLF Report. In: Medical Technology Leadership Forum, 2007 June 4-5; Georgia Institute of Technology, Atlanta, USA.
  74. Mason С Regenerative Medicine 2.0. Regenerative Med. 2007; 2(1): 11-8.
  75. Nerem R.M. Tissue engineering: the hope, the hype, and the future. Tissue Eng. 2006; 12(5): 1143-50.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: 

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies